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Alzheimer Disease (AD) is a neurodegenerative disorder and the most common form of
dementia. Histopathologically is characterized by the presence of two major hallmarks,
the intracellular neurofibrillary tangles (NFTs) and extracellular neuritic plaques (NPs)
surrounded by activated astrocytes and microglia. NFTs consist of paired helical filaments
of truncated tau protein that is abnormally hyperphosphorylated. The main component
in the NP is the amyloid-β peptide (Aβ), a small fragment of 40–42 amino acids with a
molecular weight of 4 kD. It has been proposed that the amyloid aggregates and microglia
activation are able to favor the neurodegenerative process observed in AD patients.
However, the role of inflammation in AD is controversial, because in early stages the
inflammation could have a beneficial role in the pathology, since it has been thought that
the microglia and astrocytes activated could be involved in Aβ clearance. Nevertheless the
chronic activation of the microglia has been related with an increase of Aβ and possibly
with tau phosphorylation. Studies in AD brains have shown an upregulation of complement
molecules, pro-inflammatory cytokines, acute phase reactants and other inflammatory
mediators that could contribute with the neurodegenerative process. Clinical trials and
animal models with non-steroidal anti-inflammatory drugs (NSAIDs) indicate that these
drugs may decrease the risk of developing AD and apparently reduce Aβ deposition.
Finally, further studies are needed to determine whether treatment with anti-inflammatory
strategies, may decrease the neurodegenerative process that affects these patients.
Keywords: Alzheimer disease, amyloid-β, neurodegeneration, microglia, astrocyte, neuroinflammation,
pro-inflammatory cytokine, anti-inflammatory strategies
INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia
in elderly adults. AD is clinically characterized by progressive loss
of memory and other cognitive functions. Histopathologically
is recognized by the presence of neuritic plaques (NPs) and
neurofibrillary tangles (NFTs). The origin causes of AD can
be classified as familial or sporadic. The incidence of famil-
ial cases is low (5–10%) and is related to the presence of
mutations in three different genes: presenilin-1 (PS1), presenilin-
2 (PS2), and amyloid-β precursor protein (APP-β) (Chartier-
Harlin et al., 1991; Goate et al., 1991; Murrell et al., 1991;
Levy-Lahad et al., 1995; Duff et al., 1996; Sisodia et al., 1999).
Sporadic AD represents 90–95% of total cases, and although its
etiology is multi-factorial, age is the main risk factor. Although
there are different genetic and environmental causes, all patients
have a similar clinical behavior and develop identical brain
lesions: NFTs consisting of Tau (τ) protein and NPs consist-
ing of amyloid-β (Aβ) peptides. These alterations are the final
result of post-translational modifications and involve different
genes and render AD as a complex multigenic neurodegenerative
disorder.
In addition to this multi-genic complexity in AD, now we
know that Aβ promotes an inflammatory response mediated
by microglia and astrocytes, thus activating signaling pathways
that could lead to neurodegeneration. It is currently unknown
whether brain inflammation in AD patients is the cause of the
disease or a secondary phenomenon. Although it was previ-
ously thought that the central nervous system (CNS) was an
immune-privileged site, now is well known that certain fea-
tures of inflammatory processes occur normally in response to
an injury, infection or disease. The resident CNS cells generate
inflammatory mediators, such as pro-inflammatory cytokines,
prostaglandins (PGs), free radicals, complement factors, and
simultaneously induce the production of adhesion molecules and
chemokines, which could recruit peripheral immune cells. This
review describes the cellular and molecular mediators involved in
the inflammatory process associated with AD and several possible
therapeutic approaches describe recently.
NPs AND Aβ IN THE NEURO-INFLAMMATORY PROCESS
NPs, are extracellular deposits structures that contain a highly
insoluble fibrillar Aβ core formed by fragments of 39–42 amino
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acids surrounded bymicroglia, reactive astrocytes, and dystrophic
neurites produced from degenerating neuronal processes (Iversen
et al., 1995). Aβ normally originates from APP-β (Kang et al.,
1987) through the sequential action of beta secretase and the
multi-protein gamma-secretase complex.
Aβ accumulation in the brain, in one of the main patholog-
ical processes of AD patients. The formation of these deposits
initiates a series of cellular events which are able to elicit an
immune response where resident cells such as microglia and
astrocytes could participate. Aβ accumulation in parenchyma and
blood vessels causes microglial migration and promotes acute
and chronic inflammatory responses against the aggregates, thus
inducing the production of nitric oxide (NO), reactive oxygen
species (ROS), pro-inflammatory cytokines (TNFα, IL-1β and IL-
6), and PGs (PGE2), which eventually could promote neuronal
death (Figure 1) (Akiyama et al., 2000; Kitazawa et al., 2004).
CELLULAR MEDIATORS
MICROGLIA
Microglia are resident brain cells, derived frommonocyte precur-
sors cells during embryogenesis, and are able to provide the initial
response against any injury that occurs in the CNS. Although
these cell were observed by Nissl over 100 years ago, their defini-
tive identification and characterization was performed by Mrak
(2012). Activated microglial association around NPs suggested
that microglia participate in the accumulation of the Aβ observed
in AD patients (Glenner et al., 1984); this hypothesis was sup-
ported by several studies (Rozemuller et al., 1986; Dickson et al.,
1988).
Normally, microglia exists in an inactive state; morpholog-
ically, these cells have a small soma with branching processes.
When activated by pathogens or injury, these cells suffer visible
morphological changes, including decreased branching and soma
growth, the acquisition of an amoeboid form and display a wide
variety of specific cellular surface markers (Town et al., 2005). NPs
in AD patients’ brain activate the inflammatory response medi-
ated bymicroglia and cause pro-inflammatory cytokine secretion,
which may directly cause neuronal injury.
Microglia in vitro cell cultures are able to phagocyte the amy-
loid peptide. However, ultrastructural analysis of tissues from
AD patients demonstrated that there is no presence of amy-
loid fibrils in the lysosomal compartments of local microglia
cells (Frackowiak et al., 1992). Whereas microglia has the abil-
ity to phagocyte Aβ in vitro, its phagocytosis capacity is limited.
An important observed feature was the abnormal presence of
macrophages infiltrating from the periphery, which showed amy-
loid fibers in their lysosomal compartments (Wisniewski et al.,
1991; Akiyama et al., 1996). Currently, we know that there are
two types of phagocytic cells within the CNS that are able to
initiate the innate immune response: microglia and peripheral
macrophages (Rezai-Zadeh et al., 2009; Gate et al., 2010). These
macrophages are recruited into the CNS by specific cytokines and
FIGURE 1 | Inflammation in Alzheimer’s disease. The Aβ peptide produced
by APP processing, form aggregates that activate microglia through TLRs and
RAGE receptors. These receptors in turn, activate NF-κB and AP-1
transcription factors, which induce the reactive oxygen species (ROS)
production and the expression of inflammatory cytokines (IL-1, IL-6, TNF).
These inflammatory factors directly acting on the neurons and also stimulate
the astrocytes, which amplify the pro-inflammatory signals, inducing a
neurotoxic effects. The inflammatory mediators generate by resident CNS
cells, induce the production of adhesion molecules and chemokines, which
recruit peripheral immune cells.
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chemokines, which are released during microglial and astrocytic
activation and are able to cross the blood-brain barrier.
Similarly to macrophages, microglia recognizes pathogens
through pattern recognition receptors (PRRs), which include
specific toll-like receptors (TLRs), nucleotide-oligomerization
binding domain (NOD) proteins, and C-type lectin recep-
tors. These receptors interact with pathogen-associated molecu-
lar patterns (PAMPs) or damage-associated molecular patterns
(DAMPs) to initiate the cellular defense mechanisms (Sterka and
Marriott, 2006; Rubartelli and Lotze, 2007). Thus, the forma-
tion and release of ROS, pro-inflammatory cytokines (IL-1β,
IL-6, TNF-α, and IFN-γ) (Lue et al., 2001), chemokines (MIP1α,
MIP1β, RANTES, and MCP1), and growth factors such as
macrophage colony-stimulating factor (MCSF) and complement
factors (C1q, C3, C4, and C9) (Walker et al., 1995) begin. In
addition to the before mentioned molecules, microglia is also
able to express receptors for advanced glycosilation end products
(RAGE), Fc receptors, CD40, FP receptors, and various scavenger-
type receptors (El Khoury et al., 1998; Tan et al., 1999; Walker
and Lue, 2005; Okun et al., 2010). Although microglia has the
capacity to respond to various stimuli, the presence of Aβ is
particularly important. Aβ induces a high accumulation of sur-
face molecules of type I and II major histocompatibility complex
(MHC) (McGeer et al., 1988).
Microglial cells primarily have an immunomodulatory role
and express a large variety of immune response-related antigens
and molecules; however, the specific role of microglia within the
CNS remains controversial. Microglial activation is not a sim-
ple and unique phenomenon; instead, activation is a continuous
series of events in which microglia awakens innate and adaptive
phagocytic immune responses and consistently display activa-
tion through antigens on the cellular surface (Town et al., 2005).
Under this principle, microglia displays a “variable” response, in
which a mixture of the classical activation pathway and exacer-
bated increase of alternative activation can be observed in AD
patients, which could leads to irreparable damage that result in
persistent neurodegeneration.
ASTROCYTES
Astrocytes are the most abundant glial cells present in the CNS
and have important functions in brain organization and main-
tenance (Sofroniew and Vinters, 2010). These cells interact with
neurons and are involved in neurotransmitter secretion and recy-
cling, ion homeostasis, energy metabolism regulation, synaptic
remodeling and modulation of oxidative stress, information pro-
cessing, and signal transmission (Halassa and Haydon, 2010;
Henneberger et al., 2010).
In early stages of AD, activated astrocytes are located in two
regions: the molecular layer of the cerebral cortex and near the
amyloid deposits below the pyramidal cell layer. The mecha-
nisms leading to the activation of these cells in response to the
pathological changes produced by AD are not obvious, but it has
been demonstrated that the presence of amyloid activates astro-
cytes. Activated astrocytes can phagocytose and degrade amyloid,
which suggests that they importantly contribute to the removal
of accumulated Aβ in parenchyma. Astrocytes and microglia are
activated through TLRs and RAGE-dependent pathways, thus
causing local inflammation that eventually could intensifies neu-
ronal death.
Overall, the inflammatory process in AD patients is shown
by changes in microglial morphology and astrogliosis, which is
manifested by an increase in number, size and motility of astro-
cytes. Astrocyte activation is present in many neurodegenerative
conditions, expressing high levels of glial fibrillary acidic pro-
tein (GFAP), vimentin, and nestin. Unfortunately, these changes
cause a “disruption” of normal activities in astrocytes, which
are essential for normal neuronal function. Maintenance of glu-
tamate concentration in the extracellular space is among the
normal physiological functions; altering homeostasis causes a
local neuron depolarization, which leads to citotoxic damage.
Thus, although astrocytic activation has a protective role in brain,
intense activation exacerbates neuronal damage and accelerates
disease progression.
Similarly to microglia, astrocytes quickly respond to injury;
these cells are located near the fibrilar Aβ deposits, which are
responsible for the astroglial activation observed in AD patients.
Injection of Aβ oligomeric forms into the retrosplenial cor-
tex of rats caused a significant astrocyte activation, as shown
by transcription factor NF-κB activation and the presence of
inflammatory mediators such as tumor necrosis factor (TNF-α),
interleukin 1 (IL-1β), and cyclooxygenase-2 (COX-2)(Carrero
et al., 2012). The activated astrocytes express on their cell surface,
receptors that bind the Aβ peptides such as RAGE, receptor-like
density lipoproteins, proteoglycans and various scavenger recep-
tors (Wyss-Coray et al., 2003; Medeiros and Laferla, 2013). Thus,
activated astrocytes are able to cause neurodegeneration and
express inflammation-associated factors, such as S100β, conse-
quently inducing neurite outgrowth. S100β expression correlates
with the number of dystrophic neurites in AD patients (Mrak
et al., 1996).
In astrocytes, NF-κB significantly controls chemokine and
adhesion molecules secretion, favors peripheral lymphocyte infil-
tration and increases inflammatory response (Moynagh, 2005);
this process becomes a self-regulating mechanism, which leads to
neurodegeneration.
OLIGODENDROCYTES
Although oligodendroglia is important to maintain neuron mor-
phology and function, little is known about how they are affected
by Aβ deposits However, there are studies that indicate changes
in white matter and abnormalities in myelin in AD patients
(Kobayashi et al., 2002; Roth et al., 2005). Specifically, aberra-
tions have been reported in the white matter of asymptomatic
familial AD patients, particularly in patients with mutations in
PS1 (Ringman et al., 2007). The presence of Aβ in oligoden-
drocyte cultures caused cell death. Although cell death can be
prevented by the presence of anti-inflammatory agents, morpho-
logical alterations of the cells persist, suggesting that the damage
cannot be completely reversed (Roth et al., 2005). Subsequently,
oligodendrocyte differentiation and function is affected by the
simultaneous presence of mutations in PS1 (hPS1M146V ) and
Aβ accumulation, as demonstrated in a mouse model. These
abnormalities can lead to the development of abnormal pat-
terns of myelin basic protein (MBP) (Desai et al., 2011),
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which completely alters oligodendrocyte homeostasis. Finally, the
loss of trophic support provided by these cells might lead to
increased neuronal vulnerability and inflammation, thus favoring
neurodegeneration.
MOLECULAR MEDIATORS OF INFLAMMATION IN AD
The Aβ deposition activates the acute immune response of
microglial cells and astrocytes. At the same time, amyloid
plaques are responsible for the production and the activation
of inflammation-related proteins such as complement factors,
acute-phase proteins, chemokines and cytokines like interleukin 1
(IL-1), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α),
and transforming growth factor β (TGF-β). These molecular
mediators of inflammation have been linked with a series of
concomitant deleterious and beneficial effects (Figure 2).
THE COMPLEMENT SYSTEM
The complement system is an important innate and adaptive
immune response effector. This system is composed of a number
of proteins and proteases that are activated in cascade (Forneris
et al., 2012), and it appears to have a fundamental role in neu-
rodegenerative diseases. Overall, the complement system uses the
C1q molecule, mannose-binding protein or the interaction with
the C3 multifunctional protein to recognize certain molecular
patterns on pathogens. C3 activation recruits cells with phago-
cytic activity, and Membrane Attack Complex (MAC) is formed
by binding C5–C9 (Ricklin et al., 2010). In adaptive immune
FIGURE 2 | Neuronal damage and Aβ deposition triggers microglial
and astrocytes activation and the generation of inflammation
molecular mediators. The acute production of molecules of the
complement system (C1q, C3, and C5), pro-inflammatory cytokines (IL-1,
IL-6, TNF-α), chemokines (CCL2, MIP-1α, MIP-1β, and IL-8) mediate the Aβ
clearance. However, in a chronic stage these molecules could promote an
increased expression and alteration of APP processing, Aβ deposition, Tau
phosphorylation and neurodegeneration. Also, another effect of glial cells
includes the generation of NO that promotes oxidative stress. The
inflammatory microenvironment favors the production of COX-2 in neurons
that leads to apoptosis. In contrast, it has been proposed that glial cells
could mediate neuronal survival, by the production of TGF-β and
neurotrophic factors (BDNF and NGF), but the disease progression results
in failure to repair neurons.
response, the complement system is involved in T-cell response
regulation and T-helper lymphocyte differentiation (Pekkarinen
et al., 2011).
In neurodegenerative diseases, there is a deregulation of the
classical complement pathway. Studies in AD patient brains have
revealed an increase in the immunoreactivity of C1q, C3b, C4d,
C5b-9, and MAC surrounding senile plaques (McGeer et al.,
1989; Rogers et al., 1992) and microglia surrounding the fibrillar
aggregates of Aβ in the microvasculature (Fan et al., 2007). The
co-existence of these molecules with the Aβ aggregates suggests
a possible link between classical complement pathway activation,
inflammation and pathological aggregation of Aβ. A decrease in
C1q levels has been reported in cerebrospinal fluid (CSF) of AD
patient and this result contrasts with an increase of C1q lev-
els in the CNS (Smyth et al., 1994). In vitro studies revealed
that C1q recognizes fibrillar and aggregated forms of Aβ1–42
and Aβ1–40, but not the monomeric forms. The C1q receptor
is expressed in microglia, which contributed to the belief that the
increase of this molecule in AD patient brains could affect the
phagocytosis of Aβ. However, in primary microglia rat culture
studies, exposure to Aβ1–42 and a nanomolar concentration of
C1q caused a decrease in the phagocytosis of Aβ, compared to
cultures exposed only to Aβ1–42 (Webster et al., 2000). A similar
result was observed in a transgenic mousemodel, which expressed
mutated hAPP and an absence of C1q expression (APPQ−/−).
These mice showed no change in the amount of Aβ aggregates,
but a decrease in glial cells activation was observed (Fonseca
et al., 2004), thus establishing that C1q importantly contributes
to microglial activation.
Microglia cells also produce C3. When these cells are
exposed to Aβ synthetic peptides, their activation can be
observed as well as an increase in C3 synthesis to 5-to 10
fold (Haga et al., 1993). When this molecule is inhibited,
in the brain of an hAPP transgenic model, by the overex-
pression of the soluble form of the protein related to the
complement receptor (sCrry), a 2- to 3-fold increase in Aβ
deposits formation was observed in one-year-old hAPP/sCrry
mice, which was accompanied by extensive neurodegenera-
tion (Wyss-Coray et al., 2002). APP/C3−/− double trans-
genic generation confirmed that the molecule modulated the
microglia phenotype, and promotes Aβ degradation (Maier et al.,
2008).
Complement receptor 1 (CR1) is expressed in cells with
phagocytic activity, C3b and C4b are CR1 ligands, and their
binding facilitates phagocytosis. Genome-wide association stud-
ies (GWAS) in AD patients have shown a direct relationship
between CR1 gene variants with cognitive impairment in patients
and an increase in amyloid plaque formation (Chibnik et al.,
2011).
The anaphylatoxin (C5) has been linked to excitotoxicity and
apoptosis activation in the CNS, which is believed to play an
important role in the development of neurodegenerative diseases.
This molecule also promotes chemotaxis and glial cells activa-
tion. In AD animal models, the use of the C5a receptor antagonist
(C5aR or CD88) reduces the amount of Aβ aggregates and hyper-
phosphorylated tau protein (Fonseca et al., 2009; Ager et al.,
2010). It appears that the complement system activation in AD
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might have beneficial effects for Aβ clearance; however, this acti-
vation could eventually become deregulated and favor neurotoxic
effects by promoting unwanted inflammation. For these reasons,
more studies are required to understand the changes affecting the
complement system in AD development.
CYTOKINES
Immune system cells are able to produce cytokines, which are sol-
uble proteins that mediate inflammation. In the CNS, cytokines
are produced by microglial cells and astrocytes and play a key
role in CNS development during the embryonic stages. Cytokines
are involved in the inflammatory processes of neurodegenerative
diseases. In AD, these proteins may be important in the devel-
opment of the pathology. Studies of AD patient tissues and CSF
have shown elevated levels of pro-inflammatory cytokines such as
IL-1β, IL-6, IL-10, TNF-α, and TGF-β (Blum-Degen et al., 1995;
Tarkowski et al., 2002; Mrak and Griffin, 2005; Jiang et al., 2011).
The increase of these cytokines is strongly related to microglia
activation by exposure to Aβ aggregates (Meda et al., 1999).
Animal models that overexpress the mutant hAPP protein have
shown a direct relationship between the amount of Aβ aggregates
and elevated levels of TNF-α, IL-6, IL-12, IL-1β, and IL-1α (Patel
et al., 2005). In particular, studies have been performed seeking
the relationship between each cytokine with AD.
IL-1
IL-1 is known to be able to induce APP-β mRNA expression in
endothelial cells (Goldgaber et al., 1989), which suggests that IL-
1 increasing in AD patients could be linked to Aβ formation.
In a study with AD patients, it was also proposed that IL-1 was
produced by microglial cells surrounding NPs and this cytokine
could promote S100β synthesis in astrocytes (Griffin et al., 1989).
Subsequently, it was discovered that IL-1 was a contributing fac-
tor to initiate dystrophic neurite formation in Aβ diffuse deposits
(Griffin et al., 1995). Similarly, the exposure of primary cultures
of rat cortical neurons to S100β promotes dystrophic neurite
formation and APP-β mRNA expression (Li et al., 1998). Thus,
IL-1 might promote the Aβ formation and neuronal degenera-
tion through S100β present in reactive astrocytes. Additionally,
the increase in IL-1 in AD patients might promote an increase
in p38-MAP kinase activity, which could lead to Tau hyperphos-
phorilation (Sheng et al., 2000; Li et al., 2003). IL-1β signaling
blockade decreases GSK-3β activity and Tau phosphorylation
and promotes neurogenesis through the Wnt/β-catenin pathway
(Kitazawa et al., 2011). However, it has been recently suggested
that IL-1β could promote Aβ removal (Matousek et al., 2012).
IL-6
IL-6 is produced by microglial cells and is involved in the
immunoreactivity present in patient tissues with clini-
cal dementia (Hull et al., 1996). Similarly to IL-1, IL-6
promotes APP-β expression (Ringheim et al., 1998) and
could also contribute to NFT formation by inducing Tau
phosphorylation through cdk5/p35 pathway deregulation
(Quintanilla et al., 2004). However, IL-6 overexpression
has been observed in the brain of two hAPP transgenic
models (TgCRND8 and Tg2576). This overexpression
resulted in significant gliosis, a decrease in Aβ deposits in
TgCRND8 mice brains due to phagocytic marker upregula-
tion in glial cells and increasing microglial Aβ phagocytosis.
IL-6-induced neuroinflammation, and has not any effect
on APP-β processing in TgCRND8 mice, which sug-
gests that reactive gliosis, could have a beneficial effect
in early stages of disease by promoting Aβ elimination
(Chakrabarty et al., 2010).
TNF-α
TNF-α is a cytokine that can have beneficial or harmful effects on
different neurons. This cytokine stimulates NF-κB transcription
factor which, induces the pro-inflammatory molecules expres-
sion, and promote the synthesis of neuronal survival factors
such as calbindin, manganese superoxide dismutase enzyme,
and anti-apoptotic Bcl-2 protein (Wajant et al., 2003; Kamata
et al., 2005). This cytokine can stimulate microglia glutami-
nase to release glutamate, thus generating excitotoxicity (Takeuchi
et al., 2006) and promoting the development of neurodegener-
ative diseases. In AD, the direct role of this cytokine remains
uncertain; however, TNF-α could be associated with an increased
β- and γ–secretase enzyme expression (Blasko et al., 2000; Liao
et al., 2004). In vitro models have shown that TNF-α directly
stimulates BACE1 expression, thus favoring APP processing
(Yamamoto et al., 2007). The use of soluble TNF-α inhibitors
had a protective effect on APP deregulation by decreasing amy-
loid aggregate formation and attenuating the cognitive impair-
ment observed in 3xTgAD mice exposed to chronic peripheral
inflammation (McAlpine et al., 2009). However, a long-term
suppression of the TNF-α receptor signaling pathway can sup-
press the microglial ability to efficiently remove Aβ aggregates,
thus favoring its aggregation at early stages (Montgomery et al.,
2011).
TGF-β
TGF-β; is another cytokine with pleiotropic functions, which
has an anti-apoptotic function and promotes neuronal survival.
It is believed that this cytokine is involved in neurodegenera-
tive diseases (Krieglstein et al., 2002; Konig et al., 2005). It has
been reported an increase in TGF-β1 levels in the brain of AD
patients (Flanders et al., 1995). Animal models (hAPP/TGF-β1)
have shown that TGF-β1 overexpression promotes amyloidogen-
esis in the meninges and cerebral vasculature at early stages (2–3
months) (Wyss-Coray et al., 1997). By contrast, in hAPP/TGF-
β1 transgenic mice parenchyma, there is a decrease in amyloid
plaque formation, which correlates with microglial activation
(Wyss-Coray et al., 2001). In AD patients, although TGF levels
are elevated, there is a significant decrease in the expression of
the TGF-β receptor type II (TβRII); this decrease may suggest
that the signaling pathway mediated by this receptor has signif-
icant neuroprotective functions and could be altered during the
development of the disease (Tesseur et al., 2006).
In summary, the role played by cytokines remains controver-
sial. On one hand, cytokines might favormicroglial and astrocytic
activation to promote Aβ phagocytosis and neuronal survival. On
the other hand, chronic cytokine production has been described
as contributors of neurodegeneration.
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CHEMOKINES
Chemokines are small proteins whose principal function is
to attract monocytes, macrophages, lymphocytes, neutrophils,
basophils, eosinophils, and dendritic cells toward sites in which
an inflammatory response is required. Chemokines function
through the activation of their G protein-coupled receptors and
are divided into four families, CXC, CC, C, and CX3C (Wells et al.,
1998; Cyster, 1999).
Astrocytes and microglial cells, are the main producer of
chemokines in the CNS, and their receptors are observed to be
present in neurons. Chemokines and their receptors also par-
ticipate in the CNS immune response and promote lymphocyte
migration from the lymphoid organs in order to establish the
inflammatory process (Ransohoff et al., 1996).
Evidence of the participation of chemokines in AD is the
presence of monocyte chemotactic proteins (MCP-1 or CCL2)
and chemokine receptors CCR3 and CCR5 in reactive microglia
that surround senile plaques of AD patients. By contrast, the
macrophage inflammatory protein 1α (MIP-1α) is located mainly
in neurons, and MIP-1β is located primarily in astrocytes that
surround the plaques (Ishizuka et al., 1997; Xia et al., 1998).
The differential expression of chemokines and their receptors
promotes glia-neuron communication to establish a local inflam-
matory response, which could favor Aβ phagocytosis in early
stages of AD. Similarly, it is known that this inflammation con-
tributes to Tau pathology and thereby accelerates the disease
progression (Zilka et al., 2012).
Chronic inflammation in AD promotes the increased chemo-
taxis of phagocytic cells, thus favoring microglial recruitment
around Aβ aggregates (Yamamoto et al., 2005). A recent study
of CSF from AD patients revealed increased CCL2 levels, which
correlated with cognitive decline (Westin et al., 2012). Moreover,
because of Aβ aggregation, an increase in IL-8 production
(CXCL8) is generated in neurons, which correlates with an
increase in the formation of brain-derived neurotrophic factor
(BDNF) (Ashutosh et al., 2011).
The presence of Aβ, in the microvasculature, promotes
the release of IL-8, MCP-1, MIP-1 MIP-1α, and MIP-
1β chemokines, and thereby promotes monocyte differen-
tiation into macrophages and their migration through the
blood-brain barrier (Fiala et al., 1998). CSF analysis from
AD patients also showed an increase in MCP-1 and IL-
8 chemokines levels (Galimberti et al., 2003; Correa et al.,
2011). Similarly, in vitro models have demonstrated the migra-
tion ability of lymphocytes (CD4+ and CD8+) through the
blood-brain barrier (Man et al., 2007) because of an increased
MIP-1α level.
In conclusion, chemokines in the CNS are able to promote
local and peripheral immune system cell migration in order to
establish an immune response. In AD, it has been proposed that
the chronic production of chemokines contributes to disease
progression.
CYCLOOXYGENASES
Cyclooxygenases (COX) are enzymes responsible for converting
arachidonic acid to H2 prostaglandin, which is a PG precursor.
In general, these lipidic molecules are involved in inflammation
because they cause vasodilation, thus allowing the immune sys-
tem cell transport to operate at the target site (Williams, 1978).
COX-1 and COX-2 isoforms are expressed in mammalian brain.
COX-1 is expressed in microglia and neurons located in the pons
and spinal cord that perform autonomous and sensory func-
tions. COX-2 occurs in glutamatergic neurons of hippocampus
and cortex and is thought to be involved in the modulation of
plasticity processes and long-term potentiation (Yamagata et al.,
1993; Breder et al., 1995); in pathological conditions, the pres-
ence of COX-1 in the CNS has been linked to inflammation
development, whereas COX-2 is associated with neurotoxicity.
Microglia surrounding the NPs in AD patient shows a high
expression of COX-1, which suggests inflammation (Yermakova
et al., 1999). On the other hand, COX-2 expression in the
hippocampal CA3 region appears to be related with the quan-
tity of NPs and NFTs and the observed cognitive impairment
(Ho et al., 2001). COX-2 overexpression in a triple transgenic
model (hAPP/PS1/hCOX-2) has resulted in an increase in active
Caspase-3 immuoreactivity and retinoblastoma protein phospho-
rylation (S795-pRb). The Rb protein regulates the G1 phase of
the cell cycle, but S725 phosphorylation suppresses cell growth.
In vitro studies revealed that hCOX-2 overexpression in pri-
mary cultures of cortical and hippocampal neurons derived from
transgenic mice, accelerates the apoptotic damage induced by
Aβ, causing cell cycle abnormalities (Xiang et al., 2002a). COX-
2 also promotes amyloid plaque formation in parenchyma and
increases prostaglandin E2 production. This increased plaque for-
mation, correlates with an increase in amyloid peptide formation
(Aβ1–40 and Aβ1–42) through the γ–secretase activation without
affecting the APP expression levels (Xiang et al., 2002b). Studies
performed in a mouse model using COX-2−/− deficient mice
demonstrated that the inflammatory response mediated by Aβ
was diminished, which suggested that COX-2 inhibition could
be an important target to be use for therapy (Choi and Bosetti,
2009).
The analysis of post-mortem brain tissue from AD patients
demonstrated that the maximum immunoreactivity for COX-2
and ppRb occurred in the early stages of the disease (Braak),
before occur the maximum astrocytic and microglial activation.
Contrary to in vitro observations, the post-mortem tissue analy-
sis did not support the direct relationship between the microglial
and astrocytic activation with the neuronal COX-2 and ppRb
expression in AD (Hoozemans et al., 2005).
Currently, the cause of alterations in COX-2 levels dur-
ing different stages of AD, remains unknown. However, it
has been suggested that inflammation in the early stages of
AD could promote such alterations, and IL-1β could pro-
mote an increase in COX-2 expression and PGs production
(Hoozemans et al., 2001).
NITRIC OXIDE
NO is a molecule that contributes importantly in cell signal-
ing. In the presence of oxygen, L-arginine, is converted to L-
citrulline and release NO. Nitric oxide synthase (NOS) is the
enzyme responsible for catalyzing this reaction, and it occurs
in three isoforms. In the CNS, the neuronal isoform (nNOS)
is widely distributed in neurons, astrocytes and blood vessels.
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The endothelial isoform (eNOS) is located in the hippocam-
pal pyramidal neurons, endothelial cells and some astrocytes.
The expression of the inducible isoform (iNOS) is typically
low but is increased in microglia and astrocytes during neuro-
inflammation. Under physiological conditions, it is believed that
NO regulates the release of neurotransmitters and hormones and
promotes cell survival and long-term potentiation. However, high
levels of NO are generated in inflammatory conditions, which
might contribute to synaptic transmission dysfunction, protein
and lipid oxidative damage, excitotoxicity, and neuronal death
(Liu et al., 2002; Bishop and Anderson, 2005; Calabrese et al.,
2007).
Tissue and neuronal analyses of AD patients have revealed
that Aβ is able to promote NOS expression and NO produc-
tion in microglia cells and reactive astrocytes (Goodwin et al.,
1997; Wallace et al., 1997; Akama et al., 1998). Aβ also pro-
motes the pro-inflammatory cytokines IL-1β and TNF-α lib-
eration which contribute to NO and peroxynitrite formation
(Rossi and Bianchini, 1996; Combs et al., 2001) and cause pro-
tein and lipid modifications, mitochondrial damage, apoptosis
and promote Aβ formation, increasing the γ-secretase com-
plex activity (Torreilles et al., 1999; Keil et al., 2004; Guix
et al., 2012). Under normal conditions, NO is synthesized in
the microvasculature and regulates β-secretase activity which
participate in APP processing (Austin et al., 2010). NOS2 also
favors Aβ elimination by regulating MMP-9/TIMP-1 expression,
which is a key enzyme that degrades amyloid (Ridnour et al.,
2012). In addition, it has been shown that chronic NO for-
mation may alter insulin-degrading enzyme activity (Kummer
et al., 2012). NO synthesis during AD development could
also contribute to NFT formation. In co-cultures of astrocytes
and hippocampal neurons of rats, exposure to Aβ25–35 was
found to increase NO levels, which correlated with increased
hyperphosphorylated Tau protein. Interestingly, the use of a
NOS inhibitors reduced Tau phosphorylation levels (Saez et al.,
2004).
INFLAMMATION MODULATOR TREATMENTS:
THERAPEUTICS IN AD
In the early 1990s, studies began to emerge relating the inflamma-
tion process with AD. Studies such as those of Fillit et al. (1991)
showed that certain pro-inflammatory cytokines were elevated in
AD patients.
Epidemiological studies (Li et al., 1992) indicates that sub-
jects with arthritis have a lower prevalence of AD, after which it
was proposed that this negative association could be related to
the chronic use of anti-inflammatory drugs (Dickson and Rogers,
1992). From these and other results, these drugs began to be pro-
posed as a new therapeutic approach for AD treatment. Currently,
numerous epidemiological studies, experimental in vitro and
in vivo models and clinical trials have been designed to elucidate
the relationship between modulators of inflammation and AD.
Typically, anti-inflammatory agents are divided into non-
steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids.
This section will review the mechanisms of action of both types
of anti-inflammatory agents and their role in AD and the results
of some of the most relevant epidemiological and experimental
studies. This section will also analyse the use of active and passive
immunotherapy as a therapeutic strategy for AD (Table 1).
ANTI-INFLAMMATORY DRUGS
NSAIDs are a heterogeneous group of drugs that share a common
mechanism of action, which involves COX-1 and COX-2 enzymes
inhibition either selectively or non-selectively (Vane and Botting,
1987). These enzymes catalyze arachidonic acid conversion to
prostaglandin H2 (PGH2), which is subsequently converted into
various PGs (PGE2, PGD2, PGF2α, and PGI2) and thromboxane
(TX) (Dubois et al., 1998).
PG and TX synthesis increases in occurrence of tissue dam-
age, acting as inflammation mediators, increasing blood flow and
vasodilation in the damaged tissue and increasing microvascular
permeability (Flower et al., 1976).
The results of several epidemiological studies designed to iden-
tify AD risk factors have shown that prolonged use of NSAID
could reduce AD risk. The following are the results from some of
the most representative studies conducted on different worldwide
populations.
The Sydney Old Persons Study showed that NSAID use, is sig-
nificantly lower in subjects who developed AD than in those
who did not develop any type of dementia during the study
period (Broe et al., 2000). Notably, NSAID use is not associ-
ated with any other type of dementia except AD. This result
could suggest that NSAID use in AD may act through a different
mechanism from their properties as cyclooxygenase inhibitors.
The Rotterdam study (In’T Veld et al., 2001), Multi-Institutional
Research Alzheimer’s Genetic Epidemiology Study (Yip et al.,
2005) and Canadian Study of Health and Aging (CSHA) (Coté
et al., 2012) also observed an association between the NSAID use
and a reduced AD risk. Szekely et al. conducted a meta-analysis
of six studies (the Baltimore Longitudinal Study of Aging, Cache
County Study, CSHA, Cardiovascular Health Study, Framingham
Heart Study and Monongahela Valley Independent Elders Study)
and reiterated the association between the NSAID use and a
reduced AD risk (Szekely et al., 2008). However, some studies have
failed to replicate this association. The Longitudinal Aging Study
Amsterdam observed a reduction in AD risk associated with the
use of aspirin alone and observed no association between AD
risk and other NSAIDs (Jonker et al., 2003). Bendlin et al. also
observed no significant differences in the results of neuropsycho-
logical memory and learning tests between NSAIDs users and
non-users (Bendlin et al., 2010).
Other studies have observed controversial results, such as
Fourrier et al. who observed an association between NSAIDs use
and a decrease inMini-Mental State Examination (MMSE) scores
(Fourrier et al., 1996). Similarly, Breitner et al. reported a greater
incidence of AD among NSAIDs users compared with controls
(Breitner et al., 2009).
Martin et al. obtained equally unfavorable results when testing
the effect of naproxen and celecoxib in older adults with a family
history of AD (Martin et al., 2008). In this study, subjects treated
with naproxen and those treated with celecoxib scored lower on
the MMSE than subjects treated with placebo, which suggested
a detrimental effect of the use of these drugs on cognitive per-
formance. Aisen et al. tested the effect of rofecoxib and naproxen
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Table 1 | Inflammation modulator treatments and their effects in animal models and clinical trials.
Therapy Drug Effects in animal models and clinical trials
N
SA
ID
s
Naproxen No beneficial effects reported. High frequency of adverse effects in drug-treated group, in clinical trials
Celecoxib Drug-treated group was found to score lower than placebo-treated group in cognitive tests, in clinical trials
Rofecoxib No beneficial effects reported. High frequency of adverse effects in drug-treated group, in clinical trials
Indomethacin In mice treated with this drug, lower Aβ levels in cortex and hippocampus were observed
Mefenamic acid Mice treated with this drug performed as well as healthy controls in cognitive tests
Triflusal In mice treated with this drug, a decrease in microglial and astrocytic activation, and a decrease in cytokine
levels were observed
Ibuprofen Mice treated with this drug performed as well as healthy controls in cognitive tests. However, an increase
in soluble Aβ levels and some behavior disturbances were observed in the drug-treated group
G
lu
co
co
rt
ic
oi
ds
Corticosterone/
Dexamethasone
Cortex, cerebellum and brainstem from mice treated with this drug showed increased expression of APP
and beta-secretase, Aβ deposition, tau aggregation and caspase 3, cytochrome c, IL-1 and TNF-α levels.
Drug-treated mice were found to score lower than placebo-treated mice in memory tasks
Prednisone No beneficial effects reported. Higher frequency of behavior disturbances was observed in the drug-treated
group, in clinical trials
Im
m
un
ot
he
ra
py
Aβ peptides In mice, this therapy was able to prevent synaptic loss. Clinical trials have shown some beneficial effects in
subjects who formed antibodies, but the incidence of meningoencephalitis as a side effect is notably high
Anti-Aβ antibodies In treated mice, a reduction in synaptic loss and number of dystrophic neurites and an increase in the
number of dendritic spines have been reported. In clinical trials, no beneficial effects have been reported
Tau peptides Prevention of cognitive decline and a decrease in the number of NFTs has been reported in mouse model
studies
Anti-tau antibodies A decrease in the number of NFTs has been reported in treated mice
Although most of these treatments have been successful in animal models, these beneficial results have not been reproduced in clinical trials, and even have been
cause of detrimental effects.
on patients with mild to moderate AD (Aisen et al., 2003). The
study, which lasted one year, showed no significant differences in
the performance of subjects treated with rofecoxib or naproxen or
placebo. In addition, subjects in NSAID-treated groups reported
a high frequency of adverse effects such as fatigue and dizziness
and had a significantly higher incidence of hypertension. Another
study with rofecoxib, conducted in patients with mild cognitive
impairment (MCI), suggested a deleterious effect of rofecoxib
(Thal et al., 2005).
The results of AD animal model studies appear to support
the hypothesis that the use of NSAID is beneficial, not only as
a method of preventing the disease, but also as a therapeutic
strategy. This support was observed in Tg2576 (Swe-APP) trans-
genic mice treated with indomethacin, which showed a marked
decrease in Aβ levels (Aβ1−40 and Aβ1−42) in both cortex and
hippocampus (Sung et al., 2004).
Subsequently, Joo et al. showed that mice treated with mefe-
namic acid for 3 weeks after being treated with Aβ1–42 or express-
ing Swe-APP, re-established their performance in the Morris
water maze test in a comparable way to the vehicle-treated
group (Joo et al., 2006). Coma et al. obtained similar results in
Tg2576 transgenic mice treated with Triflusal (a NSAID from the
salicylate family but a non-aspirin derivative), thus re-establishing
transgenic mice (Tg+) performance in Morris test and a condi-
tioning test (Coma et al., 2010). Although Triflusal had no effect
on reducing NP size (NPS) or number, it reduced the amount
of activated astrocytes and microglia and IL-1β and TNF-α levels
in the hippocampal CA1 region and entorhinal cortex. Van Dam
et al. observed similar results in TgAPP23 mice after treatment
with Ibuprofen (Van Dam et al., 2010).
In the animal model (5XFAD), which overexpressed the
Swedish double mutation (K670N, M671L), Florida mutation
(I716V), London mutation (V717I), and double mutation in PS1
(M146L and L286V), treatment with ibuprofen for 3 months
resulted in a reduction of the inflammatory response. However,
it is notable that there was an increase in soluble Aβ42 levels and
there was some changes in behavior, thus questioning whether
anti-inflammatory drug use may actually be beneficial for AD
treatment (Hillmann et al., 2012).
Whereas inflammation is a neuropathological feature always
present in AD, and inflammatory processes significantly con-
tribute to cell damage in this disease, previous studies performed
in vivo and in vitro suggest that NSAIDs participation in
AD occurs not only through an anti-inflammatory mechanism
but also by modulating Aβ synthesis and removal in the
CNS. Several studies have shown that NSAIDs stimulate the
Frontiers in Integrative Neuroscience www.frontiersin.org August 2013 | Volume 7 | Article 59 | 8
Meraz-Ríos et al. Neuroinflammation in Alzheimer Disease
non-amyloidogenic APP-processing pathway (Avramovich et al.,
2002), decrease β-secretase levels (Sastre et al., 2006), and reduce
the Aβ formation (Hirohata et al., 2005).
Although animal models appear to show that NSAIDs are a
promising therapeutic option, currently, no clinical trials con-
ducted with these drugs have achieved favorable results in AD
patients.
GLUCOCORTICOIDS
Similar to NSAIDs, glucocorticoids have potent anti-
inflammatory effects, which have made them strong candidates
for AD treatment. Basically, the mechanism of action of glu-
cocorticoids is based on their ability to bind to its receptors
(Glucocoticoid Receptor, GR), which is observed in the cyto-
plasm in its free form, which translocates into the nucleus after
binding to one of its ligands. When GR locate at the nucleus, it
binds to certain nucleotide sequences, glucocorticoid response
elements (GREs), which are located in the promoter region of a
variety of genes.
Depending on the type of GRE sequence to which it binds,
GR will positively or negatively regulate gene expression (Beato
et al., 1989). The importance of this binding in the inflamma-
tory process is that some genes which GR binds to and activates,
have anti-inflammatory effects such as annexin-1 (lipocortin-1),
interleukin 10 and NF-κB inhibitor (IκB-α) (Barnes, 2006). In
addition, it has also been suggested that glucocorticoids interact
directly with Aβ.
The study of post-mortem AD brains showed a decrease in
the presence of NPs in subjects under chronic treatment with
corticosteroids. No significant differences were observed in the
number of NFTs. This study also reported no association between
chronic treatment with NSAIDs and the number of NPs (Beeri
et al., 2012).
Despite its anti-inflammatory effect, the use of glucocorticoid
as a therapeutic strategy in the treatment of AD is controver-
sial, because numerous studies have associated increased levels
of glucocorticoids (cortisol), to an increased AD risk. In 1994,
Swaab et al. measured cortisol levels in post-mortem samples
of CSF and observed an 83% increase in AD subjects compared
to healthy controls (Swaab et al., 1994). These results coincide
with the results of Laske who observed significantly higher lev-
els of serum cortisol in AD patients compared with age-matched
healthy controls (Laske et al., 2009).
The majority of animal model experiments does not sup-
port the use of corticosteroids as a therapeutic strategy for AD
and suggests that these drugs promote the development of the
neuropathological features of this disease.
The treatment of rats with glucocorticoids (corticosterone and
dexamethasone) induces an increase in APP expression in cortex,
cerebellum, and brain stem (Budas et al., 1999), thus suggest-
ing an adverse effect. Additionally, there is an increase in Aβ
formation because of the increased APP and β-secretase levels.
These glucocorticoid levels also correlate with Tau accumulation
(Green et al., 2006), memory, and learning impairment (Yao et al.,
2007) and increased levels of caspase 3 and cytochrome c, which
indicates the presence of a pro-apoptotic enviroment (Li et al.,
2010). Finally, high levels of corticosterone in hippocampal cells
have a pro-inflammatory effect, thus favoring IL-1 and TNF-α
expression (Macpherson et al., 2005).
These studies indicates that the mechanisms that might
associate glucocorticoids with an increase in AD risk are
related with the increasing expression of proteins involved in
Aβ synthesis (APP and β-secretase) or promoting apoptosis
(Cotman and Anderson, 1995).
In humans, there is only one clinical trial investigating the
effect of glucocorticoids in the treatment for AD, the trial investi-
gate the used of a daily dose of prednisone or placebo for 1 year
(Aisen et al., 2000). There were no significant differences in the
cognitive performance of AD subjects treated with prednisone or
placebo at the end of treatment; however, the prednisone-treated
subjects showed a higher frequency of behavioral disturbances
compared to controls.
In general, there is little evidence to suggest the neuroprotec-
tive or therapeutic role of glucocorticoids in AD; in contrast, there
is extensive evidence of a possible neurotoxic role. Whereas it is
possible that under certain conditions these substances are actu-
ally neuroprotective, details of their mechanism of action should
be extensively evaluated in AD before a clinical testing protocol
can be considered.
IMMUNOTHERAPY
Currently, there is no consensus among researchers regarding
what triggers AD pathophysiology or which events are causes
and which are bodily responses to counteract the damage caused
by the disease. This problem has also been raised regarding
inflammation.
Whereas therapies using NSAIDs and glucocorticoids were
designed based on the idea that the immune response in AD has
an adverse effect (Blasko et al., 2004) or may be a causal factor
(McGeer and McGeer, 1995), there are other approaches which
suggest that the immune response may be beneficial because it
attempts to counteract the deleterious effects of Aβ oligomers and
Tau aggregation.
Immunotherapy is one of the therapeutic strategies designed
under these bases because it is underlying on promoting the
immune response against the altered molecules that are present
in the most distinctive histopathological lesions of the disease
(NPs and NFTs) and destroy them. This section will review the
types (anti-Aβ and anti-Tau immunotherapy) and some results
of immunotherapeutic studies with AD patients.
ANTI-Aβ IMMUNOTHERAPY
Animal studies in which the anti-Aβ immunotherapy strategy has
been tested have been promising. Buttini observed that either
active (using four different Aβ sequence fragments) or passive
immunotherapy (using 3D6 anti-Aβ and 12B4 antibodies) pre-
vent the loss of synapses in PDAPP transgenic mice (Buttini et al.,
2005).
The application of a single 3D6 anti-Aβ dose in Tg2576 mice
demonstrated that there was no reduction in the number of NPs;
nevertheless, there was a reduction in the number of dystrophic
neurites (Rozkalne et al., 2009). On the other hand, the appli-
cation of this antibody in PDAPP mice showed an increase in
the number of dendritic spines, which suggests that this anti-Aβ
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immunotherapy approach, can increase neuronal plasticity and
could contribute to the recovery of neural circuits. Subsequently,
the effect of passive immunotherapy was studied with 7B6 anti-
Aβ antibodies in Aβ APPswe/PS1dE9 mice (Spires-Jones et al.,
2009; Liu et al., 2011). The authors observed that mice had a
higher density of mono-aminergic axons in both the cortex and
hippocampus. Immunotherapy using anti-Aβ CAD106 antibod-
ies in different transgenic mouse models for APP (APP23 and
APP24) showed a reduction in the presence of Aβ in both models
(Wiessner et al., 2011).
In humans, some results suggest that anti-Aβ active
immunotherapy could be beneficial; however, the frequency
of adverse effects has been too high. In a study of active
immunotherapy using Aβ1−42 pre-aggregating (AN1792) in
combination with immunogenic adjuvant QS-21 (a saponin of
vegetable origin) observed a slower cognitive decline in subjects
responding to the treatment (forming specific antibodies) (Hock
et al., 2003; Orgogozo et al., 2003). However, 10% of the partici-
pants developed cases of aseptic meningoencephalitis. A similar
result was obtained in an additional group of patients who were
evaluated after stopping the treatment due to the adverse effects
observed. The monitoring of these patients included cognitive
testing and MRI scans to determine brain volume. Patients who
were classified as antibody producers before the suspension of
the study were tested for the presence of antibodies using ELISA;
89% of patients had antibodies at the time of investigation. These
patients positive to antibodies production, performed better on
cognitive tests than those treated with placebo, which suggests a
possible beneficial effect of the treatment. However, brain volume
loss was identical for both groups (Vellas et al., 2009).
The high incidence of aseptic meningoencephalitis among
the subjects receiving active anti-Aβ immunotherapy could
be attributed to an excessive pro-inflammatory response by
T lymphocytes. Unfortunately, passive immunization with
bapineuzumab, (a humanized murine monoclonal antibody),
showed no differences in cognitive performance in subjects
treated with bapineuzumab or placebo (Salloway et al., 2009).
ANTI-Tau IMMUNOTHERAPY
Most of the research efforts into AD immunotherapy have
focused on anti-Aβ immunotherapy. However, some studies in
animal models have also used anti-Tau immunization.
Boutajangout et al. showed that immunotherapy with the
complete 441 amino acids peptides of the human Tau protein
(hTau) prevented cognitive decline in an hTau transgenic mouse
model, which expressed the hTau transgene (Boutajangout et al.,
2010). Boimel et al. immunized the Tau transgenic mice present-
ing NFTs with phosphorylated Tau peptides. A 40% reduction in
the number of NFTs was observed (Boimel et al., 2010). Chai
et al. studied the effect of passive immunotherapy for Tau in
JNPL3 and P301S transgenic mice. Using PHF1 and MC1 anti-
bodies, the authors observed that the peripheral administration
of both antibodies significantly reduced Tau pathology compared
to controls (Chai et al., 2011). Although these results suggest that
anti-Tau immunotherapy could provide favorable results, no clin-
ical trial has been reported to date that evaluated the real effects
on humans.
These results indicate that immunotherapy, particularly anti-
Aβ active immunotherapy, could be advantageous when a strategy
that minimizes its adverse effects is achieved. Further studies are
also required with anti-Tau immunotherapy to evaluate whether
this therapy could be functional in the future.
CONCLUSION
Currently, several genetic and epidemiological studies have pro-
vided an overview of the inflammatory mechanisms involved
in AD. Although the molecular basis of the disease remains
unknown, the inflammation induced by Aβ has an important
role in the neurodegenerative process. The inflammatory process
itself is driven by microglial and astrocytic activation through the
induction of pro-inflammatory molecules and related signaling
pathways, thus leading to synaptic damage, neuronal loss, and the
activation of other inflammatory participants.
Although, the role of amyloid as a potential initiator of inflam-
mation is not obvious, its accumulation exerts an indirect effect
by activating caspases and transcription factors, such as NF-κB
and AP-1, which produce numerous inflammation amplifiers
(IL-1β, TNF-α, and IL-6). Pro-inflammatory cytokines, such as
TNF-α and IL-1β and IL-6, could act directly on the neuron and
induce apoptosis. Similarly, TNF-α and IL-1β can activate astro-
cytes, which could release factors that have the capacity to activate
microglia.
Furthermore, APP, BACE1, and PSEN expression is governed
by factors such as NF-κB. The genes encoding these proteins have
sites in their promoter regions, which are recognized by NF-κB; in
turn, the expression of these factors is upregulated by the presence
of pro-inflammatory cytokines.
Inflammatory mediators acting on neurons contribute to an
increase in amyloid production and activate microglia-mediated
inflammation. The microglia-neuron communication amplifies
the production of factors that contribute to AD-type pathology.
However, the neural response is specific for the receptor type
expressed in the different neuronal populations. For example,
TNF-α binds TNFR1, which activates the cell survival pathway
through NF-κB and the apoptotic pathway through the activation
of caspases. Conversely, TNFRII signaling only activates NF-κB.
This cascade is primarily mediated by the pro-inflammatory
cytokine IL-1β, which is expressed by microglia cells. IL-1β
may cause neuronal death via various pathways, which activate
microglia and consequently increase the release of IL-1β, thus
generating a self-sustaining mechanism that is amplified by itself.
This slow but steady inflammation state, generated for long peri-
ods in the brain eventually can destroy neurons and contribute to
the clinical symptoms observed in the disease (Figure 1).
Finally, in accordance with all the above data, particularly
because the results of the treatments used have been contra-
dictory so far and there are no clinical trials that shown that
anti-inflammatory treatments and the use of immunotherapy
are completely safe or beneficial, it is necessary to develop and
implement new strategies for AD immunological treatments.
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